Donate Now
Donate Crypto
PCRF Store
Donate Now
Donate Crypto

Historical Research

Timeline of Innovations

The Pediatric Cancer Research Foundation is celebrating a milestone in 2022 – our 40th anniversary. Over the past four decades, we have been at the vanguard of identifying and stewarding promising research. With the help of parents, physicians, and volunteers the Foundation has raised and invested over $54 Million, all of which has supported pediatric cancer research.

As we look to the future, we are a bit wistful that there is so much more to learn and do to beat the diseases that continue to rob children of their childhood. More than anything, we are super charged to do more and with greater urgency. That starts with generating the funding pediatric cancer research needs to accelerate new treatment breakthroughs, to support the next generation of researchers, and to uncover promising new directions. We like contributing to history – and with your help we will continue to rewrite it.

2022

2022 —​ Pediatric Cancer Research Foundation Laboratory at NYMC
Mitchell Cairo, M.D.
New York Medical College
2022 —​ Precision medicine to exploit Bcl2-family survival dependencies in neuroblastoma
Michael Hogarty, M.D.
The Children's Hospital of Philadelphia
2022 —​ Combining a Novel Dendritic Cell Vaccine with Checkpoint Blockade for Osteosarcoma Therapy
Eugenie Kleinerman, M.D.
University of Texas M.D. Anderson Cancer Center
2022 —​ Enhancement of Immunovirotherapy with Directed Drug Delivery for Treatment of Pediatric High-Grade Glioma
Gregory Friedman, M.D.
University of Alabama at Birmingham
2022 —​ Prospective Validation of a Prognostic Liquid Biopsy Approach for Pediatric Ewing Sarcoma
Brian Crompton, M.D.
Dana-Farber Cancer Institute
2022 —​ Intranasal Delivery of Targeting Nanoliposomal Therapeutics for Pediatric Glioma
Rintaro Hashizume, M.D., Ph.D
Ann & Robert H. Lurie Children's Hospital of Chicago-
2022 —​ Targeting Mitochondrial Pathways in Pediatric AML
Kathleen Sakamoto, M.D., Ph.D.
The Board of Trustees of the Leland Stanford Junior University
2022 —​ TACL2020-004: A risk stratified clinical trial for patients with newly diagnosed juvenile myelomonocytic leukemia
Elliot Stieglitz, M.D.
The Regents of the University of California, San Francisco (Contracts & Grants)
2022 —​ “Off-the-Shelf” Combination Cancer Immunotherapy with Oncolytic Adeno-immunotherapy and CAR NK cell therapy for Pediatric Sarcoma
Masataka Suzuki, Ph.D
Baylor College of Medicine
2022 —​ Optimizing CAR T cell immunotherapy for pediatric rhabdomyosarcoma
Chuan Yan, Ph.D.
Massachusetts General Hospital (Mass General)
2022 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital

2022

2022 — Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2022 — Optimizing CAR T cell immunotherapy for pediatric rhabdomyosarcoma
Chuan Yan, Ph.D.
Massachusetts General Hospital (Mass General)
2022 — “Off-the-Shelf” Combination Cancer Immunotherapy with Oncolytic Adeno-immunotherapy and CAR NK cell therapy for Pediatric Sarcoma
Masataka Suzuki, Ph.D
Baylor College of Medicine
2022 — TACL2020-004: A risk stratified clinical trial for patients with newly diagnosed juvenile myelomonocytic leukemia
Elliot Stieglitz, M.D.
The Regents of the University of California, San Francisco (Contracts & Grants)
2022 — Targeting Mitochondrial Pathways in Pediatric AML
Kathleen Sakamoto, M.D., Ph.D.
The Board of Trustees of the Leland Stanford Junior University
2022 — Intranasal Delivery of Targeting Nanoliposomal Therapeutics for Pediatric Glioma
Rintaro Hashizume, M.D., Ph.D
Ann & Robert H. Lurie Children's Hospital of Chicago-
2022 — Prospective Validation of a Prognostic Liquid Biopsy Approach for Pediatric Ewing Sarcoma
Brian Crompton, M.D.
Dana-Farber Cancer Institute
2022 — Enhancement of Immunovirotherapy with Directed Drug Delivery for Treatment of Pediatric High-Grade Glioma
Gregory Friedman, M.D.
University of Alabama at Birmingham
2022 — Combining a Novel Dendritic Cell Vaccine with Checkpoint Blockade for Osteosarcoma Therapy
Eugenie Kleinerman, M.D.
University of Texas M.D. Anderson Cancer Center
2022 — Precision medicine to exploit Bcl2-family survival dependencies in neuroblastoma
Michael Hogarty, M.D.
The Children's Hospital of Philadelphia
2022 — Pediatric Cancer Research Foundation Laboratory at NYMC
Mitchel Cairo, M.D.
New York Medical College

2021

2021 — Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2021 — Development of Tunable ON-OFF CAR T Cells for Safe and Durable Tumor Control
Surojit Sarkar, Ph.D.
Seattle Children's Hospital
2021 — Precision medicine to exploit Bcl2-family survival dependencies in neuroblastoma
Michael Hogarty, M.D.
The Children's Hospital of Philadelphia
2021 — Fine-tuning Chimeric Antigen Receptor Signaling to Improve CAR T Cell Therapy for Pediatric Brain Tumors
Leo Wang, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2021 — Development of small molecules to target CREB:CBP Interaction for Treatment of AML
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2021 — Combining a Novel Dendritic Cell Vaccine with Checkpoint Blockade for Osteosarcoma Therapy
Eugenie Kleinerman, M.D.
MD Anderson
2021 — Precision Medicine in Juvenile Myelomonocytic Leukemia
Elliot Stieglitz, M.D.
UC San Francisco
2021 — Prospective Validation of a Prognostic Liquid Biopsy Approach for Pediatric Ewing Sarcoma
Brian Crompton, M.D.
Dana Farber Cancer Institute
2021 — VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2021 — Audrey Coon Fund Designated Grant
Ashley Plant-Fox, M.D. and Josephine HaDuong, M.D.
CHOC Children's Hospital
2021 — Audrey Coon Fund Designated Grant
Nader Sanai, M.D.
Barrow Neurological Foundation and the Ivy Brain Tumor Center
2021 — Will Irwin Fund Designated Grant
Ashley Plant-Fox, M.D.
Ann & Robert Lurie Childrens Hospital

2020

2020 — Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2020 — Will Irwin Fund Designated Grant
Michelle Monje, M.D. Ph.D.
Stanford University
2020 — Will Irwin Fund Designated Grant
Raj Ventrakamani, M.D.
Texas Childrens Hospital
2020 — Will Irwin Fund Designated Grant
Ashley Plant, M.D.
CHOC Children's Hospital
2020 — Prospective Validation of a Prognostic Liquid Biopsy Approach for Pediatric Ewing Sarcoma
Brian Crompton, M.D.
Dana Farber Cancer Institute
2020 — Epigenetic Targeted Therapy for Pediatric Malignant Glioma-Bromodomain Inhibitor
Stewart Goldman, M.D.
Ann & Robert Lurie Childrens Hospital
2020 — Precision Medicine in Juvenile Myelomonocytic Leukemia
Elliot Stieglitz, M.D.
UC San Francisco
2020 — Development of Tunable ON-OFF CAR T Cells for Safe and Durable Tumor Control
Surojit Sarkar, Ph.D.
Seattle Children's Hospital
2020 — Development of small molecules to target CREB:CBP Interaction for Treatment of AML
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2020 — Fine-tuning Chimeric Antigen Receptor Signaling to Improve CAR T Cell Therapy for Pediatric Brain Tumors
Leo Wang, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2020 — Assessing patient preferences and an existing tool for screening for sexual dysfunction in adolescent and young adult survivors of childhood cancer
Jenna Sopfe, M.D.
University of Colorado, Denver
2020 — Targeting CDK13 in Pediatric AML
Jana Ellegast, M.D.
Dana Farber Cancer Institute
2020 — ​Combining a Novel Dendritic Cell Vaccine with Checkpoint Blockade for Osteosarcoma Therapy
Eugenie Kleinerman, M.D.
MD Anderson
2020 — ​Precision medicine to exploit Bcl2-family survival dependencies in neuroblastoma
Michael Hogarty, M.D.
The Children's Hospital of Philadelphia
2020 —​ VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2020 —​ Pediatric Cancer Research Foundation Laboratory at NYMC
Mitchell Cairo, M.D.
New York Medical College

2019

2019 —​ Role of Activated AKT in Malignant Transformation Blockage of MYCN-Induced Neuroblastoma
Ting Tao, Ph.D.
Dana Farber Cancer Institute
2019 —​ Will Irwin Fund Designated Grant
Michelle Monje, M.D. Ph.D.
Stanford University
2019 —​ Will Irwin Fund Designated Grant
Raj Ventrakamani, M.D.
Texas Childrens Hospital
2019 —​ Will Irwin Fund Designated Grant
Ashley Plant, M.D.
CHOC Children's Hospital
2019 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2019 —​ Precision Medicine in Juvenile Myelomonocytic Leukemia
Elliot Stieglitz, M.D.
UC San Francisco
2019 —​ Development of Tunable ON-OFF CAR T Cells for Safe and Durable Tumor Control
Surojit Sarkar, Ph.D.
Seattle Children's Hospital
2019 —​ Development of small molecules to target CREB:CBP Interaction for Treatment of AML
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2019 —​ Digoxin in the treatment of high-risk medulloblastoma: A new role for an old drug?
Sarah Injac, M.D.
Baylor College of Medicine
2019 —​ Epigenetic Targeted Therapy for Pediatric Malignant Glioma-Bromodomain Inhibitor
Stewart Goldman, M.D.
Ann & Robert Lurie Childrens Hospital
2019 —​ Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for Pediatric Acute Myeloid Leukemia (AML)
Agnieszka Czechowicz
Stanford University
2019 —​ Prospective Validation of a Prognostic Liquid Biopsy Approach for Pediatric Ewing Sarcoma
Brian Crompton, M.D.
Dana Farber Cancer Institute
2019 —​ Exploiting the Immunosuppressive Niche of Rhabdomyosarcomas for Novel Therapies
Lingling Chen, M.D.
Johns Hopkins University School of Medicine
2019 —​ VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2019 —​ Molecular mechanisms in PID1 medulloblastoma microenvironment
Anat Erdreich-Epstein, MD, Ph.D.
Children’s Hospital Los Angeles
2019 —​ Harnessing negative B cell selection to overcome drug-resistance in childhood ALL
Markus Müschen, MD, PhD
Beckman Research Institute of the City of Hope
2019 —​ CSV-CTC for prognosis of Neuroblastoma relapse and monitoring treatment response
Shulin Li, PhD
The University of Texas M.D. Anderson Cancer Center
2019 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College

2018

2018 —​ YAP-mediated metabolism and mitochondrial morphology in medulloblastoma
Dr. Anshu Malhotra, PhD
Emory University
2018 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2018 —​ VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2018 —​ Therapeutically Targeting DICER1-Related Solid Tumors
Kris Ann Schultz, MD
Children’s Hospitals and Clinics of Minnesota
2018 —​ Targeting prohibitin-induced therapy resistance in Wilms Tumor.
Michael Ortiz, MD
Memorial Sloan Kettering Cancer Center
2018 —​ Targeting FAK and integrin signaling in preclinical models of Ewing Sarcoma.
Brian Crompton, M.D.
Dana Farber Cancer Institute
2018 —​ Target inhibition of CREB for the Treatment of Pediatric acute Leukemias.
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2018 —​ Reprogramming the tumor microenvironment to improve medulloblastoma therapy.
Sampurna Chatterjee, PhD
Massachusetts General Hospital
2018 —​ Molecular mechanisms in PID1 medulloblastoma microenvironment
Anat Erdreich-Epstein, MD, Ph.D.
Children’s Hospital Los Angeles
2018 —​ Harnessing negative B cell selection to overcome drug-resistance in childhood ALL
Markus Müschen, MD, PhD
Beckman Research Institute of the City of Hope
2018 —​ Exosomal MicroRNA Profile and Quantitation in Serum and Cerebrospinal Fluid of Young Children with Medullosblastoma Correlate with Tumor Sub-Group, Metastatic Potential, and with Tumor Persistence, Recurrence or Eradication following Uniform Irradiation-avoiding Chemotherapy: A “Head Start4”Consortium Trial Proposal
Jonathan Finlay, MB, ChB, FRCP
The Research Institute at Nationwide Children’s Hospital
2018 —​ Evaluation of the PI3Kδ Inhibitor, idelalisib, in Childhood Acute Lymphoblastic Leukemia
Yong-mi Kim, M.D., MPH, PhD
Children’s Hospital Los Angeles
2018 —​ Epigenetic Targeted Therapy for Pediatric Malignant Glioma
Rishi Lulla, MD, MS
Ann & Robert H. Lurie Children's Hospital of Chicago
2018 —​ CSV-CTC for prognosis of Neuroblastoma relapse and monitoring treatment response
Shulin Li, PhD
The University of Texas M.D. Anderson Cancer Center
2018 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College

2017

2017 — YAP-mediated metabolism and mitochondrial morphology in medulloblastomahttps.
Dr. Anshu Malhotra, PhD
Emory University
2017 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
Children’s Hospitals and Clinics of Minnesota
2017 —​ Therapeutically Targeting DICER1-Related Solid Tumors
Kris Ann Schultz, MD
Children’s Hospitals and Clinics of Minnesota
2017 —​ The role of exosomes in neuroblastoma metastasis to the bone and bone marrow
Katharine Offer
Memorial Sloan Kettering Cancer Center
2017 —​ Targeting FAK and integrin signaling in preclinical models of Ewing Sarcoma.
Brian Crompton, M.D.
Dana Farber Cancer Institute
2017 —​ Target inhibition of CREB for the Treatment of Pediatric acute Leukemias.
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2017 —​ Molecular mechanisms in PID1 medulloblastoma microenvironment
Anat Erdreich-Epstein, MD, Ph.D.
Children’s Hospital Los Angeles
2017 —​ Integration of genomic and functional kinase inhibitor screening data reveals actionable pathways in treatment-refractory medulloblastoma
Monika Davare, Ph.D.
Oregon Health and Sciences University
2017 —​ Exosomal MicroRNA Profile and Quantitation in Serum and Cerebrospinal Fluid of Young Children with Medullosblastoma Correlate with Tumor Sub-Group, Metastatic Potential, and with Tumor Persistence, Recurrence or Eradication following Uniform Irradiation-avoiding Chemotherapy: A “Head Start4”Consortium Trial Proposal
Jonathan Finlay, MB, ChB, FRCP
The Research Institute at Nationwide Children’s Hospital
2017 —​ Evaluation of the PI3Kδ Inhibitor, idelalisib, in Childhood Acute Lymphoblastic Leukemia
Yong-mi Kim, M.D., MPH, PhD
Children’s Hospital Los Angeles
2017 —​ Biological underpinnings of heritable risk imposed by GWAS significant SNPs in childhood acute lymphoblastic Leukemia
Juhi Ojha, PhD
The Regents of the University of California, San Francisco
2017 — Acupuncture and Chinese Medicine Program at CHOC
Ruth McCarty, L.Ac
Children's Hospital of Orange County
2017 — Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College

2015-2016

2016 — YAP-mediated metabolism and mitochondrial morphology in medulloblastoma
Dr. Anshu Malhotra, PhD
Emory University
2016 — Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2016 — The pro‐oncogenic role of EZH2 and CRL4(DCAF1) in NF2 mutant gliomas
Wei Li, PhD
Penn State College of Medicine
2016 — Targeting FAK and integrin signaling in preclinical models of Ewing Sarcoma.
Brian Crompton, M.D.
Dana Farber Cancer Institute
2016 — Evaluation of the PI3Kδ Inhibitor, idelalisib, in Childhood Acute Lymphoblastic Leukemia
Yong-mi Kim, M.D., MPH, PhD
Children’s Hospital Los Angeles
2016 — Establishment of a PCRF Childhood, Adolescent, and Young Adult (CAYA) non-Hodgkin Lymphoma (NHL) Biorepository to Support Translational NHL Research”
Rodney R. Miles, MD, PhD
University of Utah
2016 — Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College
2016 — Adoptive cellular therapy to reverse local immune suppression in sol.
Courtney Crane, M.D.
Seattle Children's Research Institute
2015 — VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2015 — Targeting FAK and integrin signaling in preclinical models of Ewing Sarcoma.
Brian Crompton, M.D.
Dana Farber Cancer Institute
2015 — Target inhibition of CREB for the Treatment of Pediatric acute Leukemias.
Kathleen Sakamoto, M.D., Ph.D.
Stanford University
2015 — Research and education regarding the potential late effects of childhood cancer.
Alan Homans, M.D.
Vermont Cancer Center, University of Vermont
2015 — Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2015 — ​Pediatric cancer clinical trials program overseeing more than 100 Phase I, II or III trials.
Leo Mascarenhas, M.D., M.S.
Children’s Center for Cancer and Blood Diseases At Children's Hospital Los Angeles
2015 — ​New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D.
Childrens' Hospital Los Angeles
2015 — ​Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma.
Margarita Gutova, M.D.
Beckman Research Institute of the City of Hope
2015 — ​Markers of Risk Stratification in Fusion Negative.
Michael Arnold, M.D.
The Research Institute at Nationwide Children’s Hospital
2015 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College

2012-2014

2014 —​ Identifying and targeting Molecular Pathways Critical to Metastatic Osteosarcoma.
Jason Yuestein, M.D., Ph.D.
Baylor College of Medicine
2014 — The Future of Immunotherapy in Pediatric Cancer.
Paul Sondel, MD, Ph.D.
University of Wisconsin-Madison School of Medicine
2014 —​ Analysis of Mutational Profiles and the Impact of Germ Line TP53 Mutations in Familites with Lifraumeni.
Diane Nugent, M.D.
CHOC Children's Hospital
2014 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2014 —​ Pediatric cancer clinical trials program overseeing more than 100 Phase I, II or III trials.
Leo Mascarenhas, M.D., M.S.
Children’s Center for Cancer and Blood Diseases At Children's Hospital Los Angeles
2014 —​ Yes-Associated Protein: A Master Metabolic Regulator in Medulloblastoma.
Anna Marie Kenney, M.D.
Emory University
2014 —​ VCAM-1 as a functional biological marker for Metastatic Osteosarcoma.
Alex Yee-Chen Huang, M.D., Ph.D.
Case Western University School of Medicine
2014 —​ Research and education regarding the potential late effects of childhood cancer.
Alan Homans, M.D.
Vermont Cancer Center, University of Vermont
2014 —​ Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma.
Margarita Gutova, M.D.
Beckman Research Institute of the City of Hope
2014 —​ Targeting FAK and integrin signaling in preclinical models of Ewing Sarcoma.
Brian Crompton, M.D.
Dana Farber Cancer Institute
2014 —​ Development of a novel cellular immunotherapy approach to treating children with relapsed embryonal brain tumors.
Laurence Cooper, M.D., Ph.D.
MD Anderson Cancer Center
2014 —​ A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2013 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2013 —​ Pediatric cancer clinical trials program overseeing more than 100 Phase I, II or III trials.
Leo Mascarenhas, M.D., M.S.
Children’s Center for Cancer and Blood Diseases At Children's Hospital Los Angeles
2013 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College
2013 —​ Research and education regarding the potential late effects of childhood cancer.
Alan Homans, M.D.
Vermont Cancer Center, University of Vermont
2013 —​ Development of a novel cellular immunotherapy approach to treating children with relapsed embryonal brain tumors.
Laurence Cooper, M.D., Ph.D.
MD Anderson Cancer Center
2012 —​ Latest scientific and clinical advances in childhood hematological malignancies and stem cell transplantation.
Alfred Reiter, M.D.
University of Giessen, Germany
2012 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2012 —​ Pediatric cancer clinical trials program overseeing more than 100 Phase I, II or III trials.
Leo Mascarenhas, M.D., M.S.
Children’s Center for Cancer and Blood Diseases At Children's Hospital Los Angeles
2012 —​ Cody Camp Fellowship in Burkitt Lymphoma Research
Sanghoon Lee, Ph.D.
New York Medical College
2012 —​ Development of a novel cellular immunotherapy approach to treating children with relapsed embryonal brain tumors.
Laurence Cooper, M.D., Ph.D.
MD Anderson Cancer Center

2009-2011

2011 —​ Pediatric Hematopoietic Stem Cell Transplant and Relapsed Leukemia.
Theodore Moore, M.D.
UCLA Mattel Children's Hospital
2011 —​ Pediatric cancer clinical trials program overseeing more than 100 Phase I, II or III trials.
Stuart Siegel, M.D.
Children’s Center for Cancer and Blood Diseases At Children’s Hospital Los Angeles
2011 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College
2010 —​ Translational research using targeted therapies in pediatric malignancies.
Kathleen Sakamoto, M.D., Ph.D.
UCLA Mattel Children's Hospital
2010 —​ Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL).
J. Eric Bubbers, Ph.D.
Children's Hospital Los Angeles
2010 —​ The Head Start Consortium for the Treatment of Young Children with Malignant Embryonal Central Nervous System Tumors.
Jonathan Finlay, M.D.
Children's Hospital Los Angeles
2010 —​ Research in the development of T-cell based therapeutics for children.
Michael Jensen, M.D.
Beckman Research Institute of the City of Hope
2010 —​ New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D.
Childrens' Hospital Los Angeles
2010 —​ The Head Start Consortium for the Treatment of Young Children with Malignant Embryonal Central Nervous System Tumors.
Jonathan Finlay, M.D.
Children's Hospital Los Angeles
2010 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
New York Medical College
2010 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
Columbia University Medical Center

2006-2008

2008 —​ Research in the development of T-cell based therapeutics for children.
Michael Jensen, M.D.
Beckman Research Institute of the City of Hope
2008 —​ The Head Start Consortium for the Treatment of Young Children with Malignant Embryonal Central Nervous System Tumors.
Jonathan Finlay, M.D.
Children's Hospital Los Angeles
2008 —​ A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2008 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Columbia University Medical Center
2007 —​ New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D.
Childrens' Hospital Los Angeles
2007 —​ Research in the development of T-cell based therapeutics for children.
Michael Jensen, M.D.
Beckman Research Institute of the City of Hope
2007 —​ Development of a novel cellular immunotherapy approach to treating children with relapsed embryonal brain tumors.
Laurence Cooper, M.D., Ph.D.
MD Anderson Cancer Center
2007 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Columbia University Medical Center
2006 —​ New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D.
Childrens' Hospital Los Angeles
2006 —​ The Head Start Consortium for the Treatment of Young Children with Malignant Embryonal Central Nervous System Tumors.
Jonathan Finlay, M.D.
Children's Hospital Los Angeles
2006 —​ Research in the development of T-cell based therapeutics for children.
Michael Jensen, M.D.
Beckman Research Institute of the City of Hope
2006 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Columbia University Medical Center

2003-2005

2005 — New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D..
Childrens' Hospital Los Angeles
2005 — A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2005 — Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
Columbia University Medical Center
2004 — New Approaches to Neuroblastoma Therapy (NANT) research program.
Robert C. Seeger, M.D..
Childrens' Hospital Los Angeles
2004 — A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2004 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
Columbia University Medical Center
2003 — Growth and Neurodevelopment of Infants with Leukemia.
Thomas Kaleita, Ph.D.
University of California, Los Angeles
2003 — Latest scientific and clinical advances in childhood hematological malignancies and stem cell transplantation.
Alfred Reiter, M.D.
University of Giessen
2003 — A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2003 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, M.D.
Columbia University Medical Center

2001-2002

2002 —​ Development of an anti-cancer vaccine using non-toxic bacteria to stimulate cellular immunity to neuroblastoma.
Charles Theuer, M.D.
UCI Medical Center
2002 — A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2002 - Growth and Neurodevelopment of Infants with Leukemia.
Thomas Kaleita, Ph.D.
University California, Los Angeles
2002 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Columbia University Medical Center
2001 —​ Development of an anti-cancer vaccine using non-toxic bacteria to stimulate cellular immunity to neuroblastoma.
Charles Theuer, M.D.
UCI Medical Center
2001 —​ Cellular therapy post-transplant to prevent relapse and prolong remission in neuroblastoma patients.
Leonard Sender, M.D.
Children's Hospital of Orange County
2001 —​ A Phase I study using genetically modified clones.
Laurence Cooper, M.D., Ph.D.
Beckman Research Institute of the City of Hope
2001 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Columbia University Medical Center
2001 —​ Fellowship in the field of transplantation and graft-versus-host disease.
Amy Strelzer Manasevit Research Scholar
National Marrow Donor Program

1998-2000

2000 —​ Fellowship in the field of transplantation and graft-versus-host disease.
Amy Strelzer Manasevit Research Scholar
National Marrow Donor Program
2000 —​ Development of an anti-cancer vaccine using non-toxic bacteria to stimulate cellular immunity to neuroblastoma.
Charles Theuer, M.D.
UCI Medical Center
1999 —​ Fellowship in the field of transplantation and graft-versus-host disease.
Amy Strelzer Manasevit Research Scholar
National Marrow Donor Program
1998 —​ Development of an anti-cancer vaccine using non-toxic bacteria to stimulate cellular immunity to neuroblastoma.
Charles Theuer, M.D.
UCI Medical Center
1998-2001 — Cellular therapy post-transplant to prevent relapse and prolong remission in neuroblastoma patients.
Leonard Sender, M.D.
Children's Hospital of Orange County
1998-2000 —​ Basic, Translational and Clinical Research in Pediatric Hematology, Oncology and Stem Cell Transplantation.
Mitchell Cairo, MD
Georgetown University Medical Center

1982-1997

1997 —​ Allogeneic transplants and their capacity to transfer resistance to Leukemia and Lymphoma.
Richard J. O'Reilly, M.D.
Memorial Sloan-Kettering Cancer Center
1996 —​ Progress in the cure of childhood cancer over the past 25 years.
Denman Hammond, M.D.
National Childhood Cancer Foundation
1995 —​ Childhood Cancer: The Price of Cure
Anna Meadows, M.D.
Children's Hospital of Philadelphia
1994 —​ Recent advances in research of hematology/oncology.
Robert L. Baehner, M.D.
Children's Hospital of Los Angeles
1993 —​ The role of leukocyte transfusions in neonatal sepsis.
Society for Pediatric Research
1992 — New approaches in the treatment of CNS Leukemia.
David Poplack, M.D.
National Cancer Institute
1992 —​ The stem cell and the influence of its microenvironment on hematopoiesis.
American Pediatric Society
1991 —​ New advances in hereditary hemolytic anemias.
American Pediatric Society
1990 —​ Lymphocytes and lymphokines in health and disease.
American Pediatric Society
1988-1989 — The role of leukocyte transfusions in neonatal sepsis.
Society for Pediatric Research
1982-1997 —​ Basic, Translational, and Clinical Research in Pediatric Hematology, Oncology and Bone Marrow Transplantation.
Mitchell Cairo, M.D.
Children's Hospital of Orange County

Call us

800.354.7273
Facebook Twitter Youtube Instagram Linkedin

Sign up for our Newsletter

About

Events

Contribute

Powering Cures, Realizing Futures

Donate Now

Contact

2151 Michelson Dr., Suite 180,
Irvine, CA 92612

Tax id #95-3772528
info@pcrf-kids.org

PCRF 2020 Form 990

Privacy Policy

Non-Discrimination Policy